PTC Therapeutics (PTCT) News Today $39.23 -3.15 (-7.43%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 7.4% - Should You Sell?PTC Therapeutics (NASDAQ:PTCT) Shares Down 7.4% - Here's WhyNovember 15 at 2:29 PM | marketbeat.comPTC Therapeutics Gains Buy Rating Following FDA Approval of Groundbreaking Gene Therapy KebilidiNovember 14 at 1:06 PM | markets.businessinsider.comPTC Therapeutics price target raised to $45 from $43 at BarclaysNovember 14 at 1:06 PM | markets.businessinsider.comPTC Therapeutics’ AADC deficiency gene therapy granted FDA approvalNovember 14 at 3:02 AM | markets.businessinsider.comBrokerages Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $40.38November 14 at 2:09 AM | americanbankingnews.comUS FDA approves PTC Therapeutics' gene therapy for ultra-rare disorderNovember 13, 2024 | reuters.comPTC Therapeutics Announces FDA Approval of AADC Deficiency Gene TherapyNovember 13, 2024 | prnewswire.comStockNews.com Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Buy"November 13, 2024 | americanbankingnews.comBarclays Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock PriceBarclays boosted their target price on shares of PTC Therapeutics from $31.00 to $43.00 and gave the company an "equal weight" rating in a research report on Monday.November 11, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Recommendation of "Hold" from AnalystsPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating, six havNovember 9, 2024 | marketbeat.comPTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...November 8, 2024 | finance.yahoo.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Analyst UpgradePTC Therapeutics (NASDAQ:PTCT) Shares Gap Up on Analyst UpgradeNovember 8, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $48.00Robert W. Baird raised their target price on PTC Therapeutics from $44.00 to $48.00 and gave the company an "outperform" rating in a report on Friday.November 8, 2024 | marketbeat.comPTC Therapeutics: Strong Q3 Performance Amid Market and Regulatory Challenges, Holds Rating Amid Mixed Future OutlookNovember 8, 2024 | markets.businessinsider.comPTC Therapeutics Reports Strong Q3 2024 PerformanceNovember 8, 2024 | markets.businessinsider.comPTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comPTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Hits New 1-Year High - Here's WhyPTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month High - What's Next?November 7, 2024 | marketbeat.comEarnings Preview For PTC TherapeuticsNovember 7, 2024 | benzinga.comPTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 6, 2024 | finance.yahoo.comPTC Therapeutics to Participate at Upcoming Investor ConferencesNovember 4, 2024 | prnewswire.comPTC Therapeutics, Inc.: PTC Therapeutics Announces FDA Acceptance of Translarna NDA ResubmissionNovember 1, 2024 | finanznachrichten.dePTC Therapeutics (PTCT) to Release Earnings on ThursdayPTC Therapeutics (NASDAQ:PTCT) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639800)October 31, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127%October 30, 2024 | finance.yahoo.comPTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year High - Time to Buy?PTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year High - Here's WhyOctober 30, 2024 | marketbeat.comPTC Therapeutics Announces FDA Acceptance of Translarna™ NDA ResubmissionOctober 30, 2024 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by Assenagon Asset Management S.A.Assenagon Asset Management S.A. increased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 32.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 492,464 shares of the biopharmaceuOctober 27, 2024 | marketbeat.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 25, 2024 | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year High - Here's What HappenedPTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week High - Here's WhyOctober 24, 2024 | marketbeat.comPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial ResultsOctober 24, 2024 | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Shares Up 4.5% - Should You Buy?PTC Therapeutics (NASDAQ:PTCT) Trading Up 4.5% - Still a Buy?October 23, 2024 | marketbeat.comHold Rating for PTC Therapeutics Amidst Regulatory Hurdles with TranslarnaOctober 22, 2024 | markets.businessinsider.comPTC Therapeutics: CHMP Again Recommends Against Translarna RenewalOctober 18, 2024 | marketwatch.comPTC: CHMP Maintains Negative Opinion On Renewal Of Conditional Marketing Authorization Of TranslarnaOctober 18, 2024 | markets.businessinsider.comCHMP Maintains Negative Opinion on Translarna™ ReexaminationOctober 18, 2024 | prnewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and PTC Therapeutics (PTCT)October 15, 2024 | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Hold" from BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has received a consensus rating of "Hold" from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell rating, five have assigned a hold rating, six have issued a buy rOctober 15, 2024 | marketbeat.comPTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial ResultsOctober 14, 2024 | prnewswire.comShort Interest in PTC Therapeutics, Inc. (NASDAQ:PTCT) Declines By 18.2%PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,270,000 shares, a decline of 18.2% from the September 15th total of 5,220,000 shares. Based on an average daily volume of 623,500 shares, the days-to-cover ratio is presently 6.8 days.October 13, 2024 | marketbeat.comSG Americas Securities LLC Buys New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)SG Americas Securities LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 22,514 shares of the biopharmaceutical company's stock, valued at aOctober 13, 2024 | marketbeat.comMorgan Stanley Remains a Hold on PTC Therapeutics (PTCT)October 11, 2024 | markets.businessinsider.comFY2025 EPS Estimates for PTC Therapeutics, Inc. Boosted by William Blair (NASDAQ:PTCT)PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at William Blair raised their FY2025 earnings estimates for shares of PTC Therapeutics in a research note issued on Tuesday, October 8th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will poOctober 11, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down - Here's What HappenedPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down - Here's WhyOctober 10, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Receives New Coverage from Analysts at Raymond JamesRaymond James began coverage on shares of PTC Therapeutics in a report on Thursday. They issued a "market perform" rating on the stock.October 10, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Trading Down 3.4% - What's Next?PTC Therapeutics (NASDAQ:PTCT) Shares Down 3.4% - Here's What HappenedOctober 9, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Accolade (ACCD)October 9, 2024 | markets.businessinsider.comMillennium Management LLC Increases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Millennium Management LLC grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 123.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 317,579 shares of the bOctober 9, 2024 | marketbeat.comPTC Therapeutics Hits 52-Week High After Drug-Study ResultsOctober 8, 2024 | marketwatch.comPositive Clinical Trials and FDA Advancements Bolster Buy Rating for PTC TherapeuticsOctober 8, 2024 | markets.businessinsider.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.570.55▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼115▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IONS News EBS News SAGE News INSM News PCVX News RDY News SRPT News CTLT News RVMD News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTCT Stock Alerts